6-(4-((4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide

ID: ALA5278372

Max Phase: Preclinical

Molecular Formula: C46H51N13O7

Molecular Weight: 898.00

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(Cc5cn(CCCCCC(=O)Nc6cccc7c6C(=O)N(C6CCC(=O)NC6=O)C7=O)nn5)CC4)cn3)nc2n(C2CCCC2)c1=O

Standard InChI: InChI=1S/C46H51N13O7/c1-27-33-24-48-46(52-41(33)58(30-9-5-6-10-30)44(65)39(27)28(2)60)50-36-16-14-31(23-47-36)56-21-19-55(20-22-56)25-29-26-57(54-53-29)18-7-3-4-13-37(61)49-34-12-8-11-32-40(34)45(66)59(43(32)64)35-15-17-38(62)51-42(35)63/h8,11-12,14,16,23-24,26,30,35H,3-7,9-10,13,15,17-22,25H2,1-2H3,(H,49,61)(H,51,62,63)(H,47,48,50,52)

Standard InChI Key: JSJGLYIYFOFJTA-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 66 74  0  0  0  0  0  0  0  0999 V2000
   -8.4819   -0.1253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7673    0.2869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0555   -0.1250    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0555   -0.9501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7656   -1.3619    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4819   -0.9538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1963    0.2873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.1960    1.1123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4814    1.5246    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7671    1.1119    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -7.0524    1.5245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.9663    2.3447    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.1595    2.5162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.7470    1.8020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.2990    1.1890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.3408   -1.3627    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6262   -0.9501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.6259   -0.1249    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9131    0.2856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1982   -0.1269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.1967   -0.9480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.9085   -1.3645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4836    0.2854    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.4836    1.1108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7690    1.5233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0543    1.1107    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0543    0.2854    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7690   -0.1269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3396    1.5233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6251    1.1107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1283    1.4462    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6802    0.8333    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2678    0.1190    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5389    0.2905    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5054    0.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9180    0.1186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7432    0.1186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1558   -0.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9810   -0.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3936   -1.3105    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2188   -1.3105    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9810   -2.0252    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.6314   -0.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2189    0.1188    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6309    0.8309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4564    0.8309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8683    0.1206    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4601   -0.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0154   -1.2056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6760   -0.0461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7668   -0.8658    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4815   -1.2784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1961   -0.8658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9107   -1.2784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9107   -2.1036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1961   -2.5162    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4815   -2.1036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8018   -2.0026    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.2594    0.5373    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    7.7668   -2.5162    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6253   -2.5162    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -8.4814    2.3498    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9109   -0.1253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9107    1.5249    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  -10.6253    1.1123    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -9.9107    2.3501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  1  7  1  0
  8  7  2  0
  9  8  1  0
 10  9  1  0
  2 10  1  0
 11 10  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 11  1  0
  4 16  1  0
 16 17  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 17 22  1  0
 23 20  1  0
 23 24  1  0
 25 24  1  0
 26 25  1  0
 27 26  1  0
 23 28  1  0
 28 27  1  0
 26 29  1  0
 29 30  1  0
 31 30  2  0
 31 32  1  0
 32 33  1  0
 33 34  2  0
 34 30  1  0
 32 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 40 41  1  0
 40 42  2  0
 41 43  1  0
 44 43  2  0
 45 44  1  0
 46 45  2  0
 47 46  1  0
 48 47  2  0
 43 48  1  0
 48 49  1  0
 47 50  1  0
 50 51  1  0
 51 49  1  0
 52 51  1  0
 52 53  1  0
 54 53  1  0
 55 54  1  0
 56 55  1  0
 52 57  1  0
 57 56  1  0
 49 58  2  0
 50 59  2  0
 57 60  2  0
 55 61  2  0
  9 62  2  0
  7 63  1  0
  8 64  1  0
 64 65  2  0
 64 66  1  0
M  END

Associated Targets(Human)

CDK4 Tclin Protein cereblon/Cyclin-dependent kinase 4 (68 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Protein cereblon/Cyclin-dependent kinase 6 (113 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type:	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 898.00	Molecular Weight (Monoisotopic): 897.4034	AlogP: 4.07	#Rotatable Bonds: 15
Polar Surface Area: 239.61	Molecular Species: NEUTRAL	HBA: 17	HBD: 3
#RO5 Violations: 2	HBA (Lipinski): 20	HBD (Lipinski): 3	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.14	CX Basic pKa: 5.66	CX LogP: 4.03	CX LogD: 4.02
Aromatic Rings: 5	Heavy Atoms: 66	QED Weighted: 0.08	Np Likeness Score: -1.25

References

1. Marak BN, Dowarah J, Khiangte L, Singh VP.. (2020) A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents., 203 [PMID:32707525] [10.1016/j.ejmech.2020.112571]
2. Gray, N S NS and 12 more authors. 1998-07-24 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. [PMID:9677190]
3. Kubo, A A and 9 more authors. 1999-12 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. [PMID:10632371]
4. Soni, R R and 7 more authors. 2000-09-07 Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. [PMID:10973815]
5. Lane, M E ME and 9 more authors. 2001-08-15 A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. [PMID:11507069]
6. Tavares, Francis X FX and 7 more authors. 2004-09-09 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. [PMID:15341487]
7. Fry, David W DW and 10 more authors. 2004-11 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. [PMID:15542782]
8. Pennati, Marzia M and 12 more authors. 2005-09 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. [PMID:16170024]
9. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N. 2006-03-24 Selectivity and potency of cyclin-dependent kinase inhibitors. [PMID:16584130]
10. DePinto, Wanda W and 19 more authors. 2006-11 In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. [PMID:17121911]
11. Joshi, Kalpana S KS and 7 more authors. 2007-03 In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. [PMID:17363486]
12. Squires, Matthew S MS and 7 more authors. 2009-02 Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [PMID:19174555]
13. Cirstea, D D and 15 more authors. 2013-12 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. [PMID:23807770]
14. Gelbert, Lawrence M LM and 16 more authors. 2014-10 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. [PMID:24919854]
15. Paiva, Cody C and 8 more authors. 2015 Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. [PMID:26606677]
16. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC. 2016-05 Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. [PMID:26826116]
17. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878]
18. Wang, Yan Y and 10 more authors. 2018-03-01 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. [PMID:29429832]
19. Tear, Westley F and 16 more authors. 2020-01-23 Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. [PMID:31846577]
20. Wu, Tizhi and 6 more authors. 2020-11-25 Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. [PMID:32866383]

6-(4-((4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source